Day JM - Search Results

1

17Beta-hydroxysteroid dehydrogenase Type 1 and Type 2: association between mRNA expression and activity in cell lines.

Day JM, Tutill HJ, Newman SP, Purohit A, Lawrence HR, Vicker N, Potter BV, Reed MJ. Day JM, et al. Mol Cell Endocrinol. 2006 Mar 27;248(1-2):246-9. doi: 10.1016/j.mce.2006.01.011. Epub 2006 Feb 21. Mol Cell Endocrinol. 2006. PMID: 16490301

2

The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer.

Purohit A, Tutill HJ, Day JM, Chander SK, Lawrence HR, Allan GM, Fischer DS, Vicker N, Newman SP, Potter BV, Reed MJ. Purohit A, et al. Among authors: day jm. Mol Cell Endocrinol. 2006 Mar 27;248(1-2):199-203. doi: 10.1016/j.mce.2005.12.003. Epub 2006 Jan 18. Mol Cell Endocrinol. 2006. PMID: 16414180

3

BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure.

Day JM, Foster PA, Tutill HJ, Newman SP, Ho YT, Leese MP, Potter BV, Reed MJ, Purohit A. Day JM, et al. Br J Cancer. 2009 Feb 10;100(3):476-86. doi: 10.1038/sj.bjc.6604873. Epub 2009 Jan 20. Br J Cancer. 2009. PMID: 19156141 Free PMC article.

4

17ß-hydroxysteroid dehydrogenase inhibitors.

Day JM, Tutill HJ, Purohit A. Day JM, et al. Minerva Endocrinol. 2010 Jun;35(2):87-108. Minerva Endocrinol. 2010. PMID: 20595938 Review.

5

The role of 17beta-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer cells.

Newman SP, Ireson CR, Tutill HJ, Day JM, Parsons MF, Leese MP, Potter BV, Reed MJ, Purohit A. Newman SP, et al. Among authors: day jm. Cancer Res. 2006 Jan 1;66(1):324-30. doi: 10.1158/0008-5472.CAN-05-2391. Cancer Res. 2006. PMID: 16397246

6

Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.

Allan GM, Lawrence HR, Cornet J, Bubert C, Fischer DS, Vicker N, Smith A, Tutill HJ, Purohit A, Day JM, Mahon MF, Reed MJ, Potter BV. Allan GM, et al. Among authors: day jm. J Med Chem. 2006 Feb 23;49(4):1325-45. doi: 10.1021/jm050830t. J Med Chem. 2006. PMID: 16480268

7

Focused libraries of 16-substituted estrone derivatives and modified e-ring steroids: inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.

Vicker N, Lawrence HR, Allan GM, Bubert C, Smith A, Tutill HJ, Purohit A, Day JM, Mahon MF, Reed MJ, Potter BV. Vicker N, et al. Among authors: day jm. ChemMedChem. 2006 Apr;1(4):464-81. doi: 10.1002/cmdc.200500087. ChemMedChem. 2006. PMID: 16892382

8

Effects of mutations and glycosylations on STS activity: a site-directed mutagenesis study.

Stengel C, Newman SP, Day JM, Tutill HJ, Reed MJ, Purohit A. Stengel C, et al. Among authors: day jm. Mol Cell Endocrinol. 2008 Feb 13;283(1-2):76-82. doi: 10.1016/j.mce.2007.11.012. Epub 2007 Nov 22. Mol Cell Endocrinol. 2008. PMID: 18180093

9

17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.

Day JM, Foster PA, Tutill HJ, Parsons MF, Newman SP, Chander SK, Allan GM, Lawrence HR, Vicker N, Potter BV, Reed MJ, Purohit A. Day JM, et al. Int J Cancer. 2008 May 1;122(9):1931-40. doi: 10.1002/ijc.23350. Int J Cancer. 2008. PMID: 18183589

10

Novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: templates for design.

Allan GM, Vicker N, Lawrence HR, Tutill HJ, Day JM, Huchet M, Ferrandis E, Reed MJ, Purohit A, Potter BV. Allan GM, et al. Among authors: day jm. Bioorg Med Chem. 2008 Apr 15;16(8):4438-56. doi: 10.1016/j.bmc.2008.02.059. Epub 2008 Mar 7. Bioorg Med Chem. 2008. PMID: 18329273

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

147 results

Search Page

Filters